Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Michelle DeMeo"'
Autor:
Tal Sella, Yue Zheng, Nabihah Tayob, Kathryn J. Ruddy, Rachel A. Freedman, Chau Dang, Denise Yardley, Steven J. Isakoff, Vicente Valero, Michelle DeMeo, Harold J. Burstein, Eric P. Winer, Antonio C. Wolff, Ian Krop, Ann H. Partridge, Sara M. Tolaney
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-9 (2022)
Abstract In the ATEMPT trial, adjuvant trastuzumab emtansine (T-DM1) compared to paclitaxel plus trastuzumab (TH) for stage I HER2-positive breast cancer improved patient-reported outcomes (PROs), while maintaining excellent disease outcomes. We repo
Externí odkaz:
https://doaj.org/article/db47278c15ae47048316e04bc579a690
Autor:
Romualdo Barroso-Sousa, Paolo Tarantino, Nabihah Tayob, Chau Dang, Denise A. Yardley, Steven J. Isakoff, Vicente Valero, Meredith Faggen, Therese Mulvey, Ron Bose, Jiani Hu, Douglas Weckstein, Antonio C. Wolff, Katherine Reeder-Hayes, Hope S. Rugo, Bhuvaneswari Ramaswamy, Dan Zuckerman, Lowell Hart, Vijayakrishna K. Gadi, Michael Constantine, Kit Cheng, Frederick Briccetti, Bryan Schneider, Audrey Merrill Garrett, Kelly Marcom, Kathy Albain, Patricia DeFusco, Nadine Tung, Blair Ardman, Rita Nanda, Rachel C. Jankowitz, Mothaffar Rimawi, Vandana Abramson, Paula R. Pohlmann, Catherine Van Poznak, Andres Forero-Torres, Minetta Liu, Kathryn J. Ruddy, Yue Zheng, Shoshana M. Rosenberg, Richard D. Gelber, Lorenzo Trippa, William Barry, Michelle DeMeo, Harold Burstein, Ann Partridge, Eric P. Winer, Ian Krop, Sara M. Tolaney
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-7 (2022)
Abstract The excellent outcomes seen in patients treated with adjuvant trastuzumab emtansine (T-DM1) in the ATEMPT trial and the favorable toxicity profile associated with this agent make T-DM1 a potential therapeutic option for select patients with
Externí odkaz:
https://doaj.org/article/e88fcc1488804534afd42026e28dc869
Autor:
Sara M Tolaney, Paolo Tarantino, Noah Graham, Nabihah Tayob, Laia Parè, Guillermo Villacampa, Chau T Dang, Denise A Yardley, Beverly Moy, P Kelly Marcom, Kathy S Albain, Hope S Rugo, Matthew J Ellis, Iuliana Shapira, Antonio C Wolff, Lisa A Carey, Romualdo Barroso-Sousa, Patricia Villagrasa, Michelle DeMeo, Molly DiLullo, Jorge Gomez Tejeda Zanudo, Jakob Weiss, Nikhil Wagle, Ann H Partridge, Adrienne G Waks, Clifford A Hudis, Ian E Krop, Harold J Burstein, Aleix Prat, Eric P Winer
Publikováno v:
The Lancet Oncology. 24:273-285
Autor:
Anna Weiss, Tianyu Li, Neelam V Desai, Nadine M Tung, Philip D Poorvu, Ann H Partridge, Faina Nakhlis, Laura Dominici, Natalie Sinclair, Laura M Spring, Meredith Faggen, Michael Constantine, Ian E Krop, Michelle DeMeo, Eileen Wrabel, Jillian Alberti, Sona Chikarmane, Nabihah Tayob, Tari A King, Sara M Tolaney, Eric P Winer, Elizabeth A Mittendorf, Adrienne G Waks
Publikováno v:
Journal of the American College of Surgeons.
Autor:
Jennifer R. Bellon, Nabihah Tayob, David D. Yang, Jordan Tralins, Chau T. Dang, Steven J. Isakoff, Michelle DeMeo, Harold J. Burstein, Ann H. Partridge, Eric P. Winer, Ian E. Krop, Sara M. Tolaney
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 113:117-124
Autor:
P. Kelly Marcom, Ann H. Partridge, Hope S. Rugo, Ron Bose, Denise A. Yardley, Douglas Weckstein, Katherine E. Reeder-Hayes, Harold J. Burstein, Michael Constantine, Rita Nanda, Jiani Hu, Patricia DeFusco, Nadine Tung, William T. Barry, Ian E. Krop, Chau T. Dang, Bhuvaneswari Ramaswamy, Frederick Briccetti, Vijayakrishna K. Gadi, V. Valero, Lorenzo Trippa, Sara M. Tolaney, Kit L. Cheng, Eric P. Winer, Antonio C. Wolff, Lowell L. Hart, Michelle Demeo, Blair Ardman, Steven J. Isakoff, Bryan P. Schneider, Kathryn J. Ruddy, Therese M. Mulvey, Rachel C. Jankowitz, Meredith Faggen, Dan Sayam Zuckerman, Kathy S. Albain, A. Merrill Garrett
Publikováno v:
Cancer Research. 80:P2-13
Background: CRA is a surrogate for ovarian toxicity and associated risk of infertility and long-term menopausal symptoms. Therefore, it is important to assess and report the rate of CRA when we study a new neoadjuvant treatment regimen. In the Adjuva
Autor:
Rachel A. Freedman, Sara M. Tolaney, D. A. Yardley, Michalina Janiszewska, Heather A. Parsons, Erica L. Mayer, O Metzger Filho, Michelle Demeo, Ian E. Krop, Laura Spring, Aditya Bardia, CL Arteaga, H Guo, G. Viale, Ta King, EP Winer, Eileen Wrabel, AH Partridge, Adrienne G. Waks, IA Mayer, Kornelia Polyak
Publikováno v:
Cancer Research. 79:P1-15
This abstract was withdrawn by the authors. Citation Format: Metzger Filho O, Janiszewska M, Guo H, Yardley D, Mayer I, Spring L, Arteaga C, Wrabel E, DeMeo M, Freedman R, Tolaney S, Waks A, Bardia A, Parsons H, Partridge A, Mayer E, King T, Polyak K
Autor:
Lowell L. Hart, Michelle Demeo, Minetta C. Liu, P. Kelly Marcom, Ron Bose, Douglas Weckstein, Ann H. Partridge, Blair Ardman, A. Merrill Garrett, Rita Nanda, Catherine Van Poznak, Andres Forero-Torres, Vicente Valero, Hope S. Rugo, Jiani Hu, Dan Sayam Zuckerman, Yue Zheng, Sara M. Tolaney, Eric P. Winer, Nabihah Tayob, Katherine E. Reeder-Hayes, Kit Cheng, Harold J. Burstein, Chau T. Dang, Patricia DeFusco, Vijayakrishna K. Gadi, Ian E. Krop, Therese M. Mulvey, Bryan P. Schneider, Rachel C. Jankowitz, Mothaffar F. Rimawi, Frederick Briccetti, Shoshana M. Rosenberg, Kathryn J. Ruddy, Nadine Tung, Vandana G. Abramson, Steven J. Isakoff, Tal Sella, Meredith Faggen, Bhuvaneswari Ramaswamy, Antonio C. Wolff, Paula R. Pohlmann, Michael Constantine, Kathy S. Albain, Denise A. Yardley
Publikováno v:
Breast cancer research and treatment. 189(1)
Chemotherapy-related amenorrhea (CRA) is a surrogate for ovarian toxicity and associated risk of infertility and premature menopause. Here, we compare CRA rate with paclitaxel (T)-trastuzumab (H) to that with ado-trastuzumab emtansine (T-DM1). Patien
Autor:
Nadine Tung, Mark E. Robson, Steffen Ventz, Adam Brufsky, Gerburg M. Wulf, Judy Garber, Nan Lin, Nick Wagle, Eddy S. Yang, Lisa A. Carey, Melissa E. Hughes, Alan D. D'Andrea, Michelle E. Melisko, Antonio C. Wolff, Colby Jenkins, Tarah J. Ballinger, Eric P. Winer, Susan M. Domchek, Ian E. Krop, Rita Nanda, Payal D. Shah, Shaveta Vinayak, Cesar A. Santa-Maria, Michelle Demeo, Paul K. Marcom
PURPOSE Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi), is approved for the treatment of human epidermal growth factor receptor 2 (HER2)–negative metastatic breast cancer (MBC) in germline (g) BRCA1/ 2 mutation carriers. Olaparib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2d957314aca664977912fc4e904535e
Autor:
Michelle Demeo, Chau T. Dang, EP Winer, V. Valero, Sara M. Tolaney, Jennifer R. Bellon, Nabihah Tayob, Harold J. Burstein, J. Tralins, Denise A. Yardley, A.H. Partridge, David D. Yang, SJ Isakoff, Ian E. Krop
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 111:S34
Purpose/Objective(s) Anti-HER2 therapy improves local control in women with HER2+ breast cancer. This retrospective analysis evaluates the efficacy and safety of radiation therapy (RT) across a range of RT doses, targets, and schedules among patients